Ivonescimab and paclitaxel for advanced appendix cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs—ivonescimab, which helps the immune system fight cancer, and paclitaxel, a chemotherapy drug given directly into the belly—for people with advanced appendix cancer that has spread. The goal is to see if this combination can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with appendix cancer that cannot be removed with surgery and has spread.
- You have had no more than two prior cancer treatments.
- You are able to take care of yourself (ECOG performance status 0-2).
- Your kidney, liver, and blood counts are within acceptable ranges.
- You have no significant bowel blockage or recent major bowel surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment that combines chemotherapy given directly into the abdomen (intraperitoneal) with standard systemic chemotherapy for people whose gastrointestinal cancer has spread to the lining of the abdomen (peritoneal carcinomatosis). It aims to control the cancer and improve how patients feel.
This trial tests a chemotherapy drug (paclitaxel) given directly into the belly for people whose appendix cancer has spread inside the belly and cannot be surgically removed. The goal is to see if this approach is safe and helps shrink tumors.
This study tests a new combination of two drugs for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help control the cancer and improve outcomes.
This trial tests a combination of two drugs—nab-paclitaxel (a chemotherapy drug) and cadonilimab (an immunotherapy drug)—for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can help shrink or control the cancer when other treatments haven't been tried yet.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This trial tests whether adding a new drug called ivonescimab to standard chemotherapy helps shrink advanced colon cancer before surgery. It may improve the chances of removing all the cancer and reduce the risk of it coming back.
Hear when a new Ivonescimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.